glp 1 court case Ozempic Lawsuit for Blindness, Stomach Paralysis and Injury Claims GLP‑1 real‑world data for obesity:

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).

Authored by a functional medicine expert with a background in endocrinology, this guide distills cutting-edge science and clinical experience into practical strategies so you can use GLP-1 peptides safely and effectively as part of a personalized health plan

Learn how to start and convert your appropriate type 1 diabetes and type 2 diabetes patients over 1 year of age to once-daily Tresiba (insulin degludec)

Mike Saltaformaggio is a passionate trial lawyer known for his unrelenting advocacy of his clients rights inside and outside the civil courtroom.

The bigger message is that these agents are pushing us toward a more integrated cardiometabolic model of care, in which obesity, heart failure, kidney disease, liver disease, and vascular risk are treated as connected biology rather than asseparate silos.